2012-5039. National Institute on Drug Abuse; Notice of Closed Meetings  

  • Start Preamble Start Printed Page 12858

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meetings.

    The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

    .

    Name of Committee: National Institute on Drug Abuse Special Emphasis Panel NIDA-K Special Emphasis Panel (SEP).

    Date: March 6, 2012.

    Time: 4:30 p.m. to 5:30 p.m.

    Agenda: To review and evaluate grant applications.

    Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW., Washington, DC 20015.

    Contact Person: Nadine Rogers, Ph.D., Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4229, MSC 9550, Bethesda, MD 20892-9550, 301-402-2105, rogersn2@nida.nih.gov

    This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

    Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Collaborative Clinical Trials in Drug Abuse.

    Date: March 13, 2012.

    Time: 11 a.m. to 2 p.m.

    Agenda: To review and evaluate grant applications.

    Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892-9550, 301-402-6626, gm145a@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Multisite Medications Development for SUDs.

    Date: March 15, 2012.

    Time: 11 a.m. to 2 p.m.

    Agenda: To review and evaluate grant applications.

    Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892-9550, 301-402-6626, gm145a@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, 2012 Translational Avant Garde Review (DP1).

    Date: March 27, 2012.

    Time: 9 a.m. to 5 p.m.

    Agenda: To review and evaluate grant applications.

    Place: Hilton Garden Inn, 7301 Waverly Street, Bethesda, MD 20814.

    Contact Person: Scott A. Chen, Ph.D., Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4234, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550, 301-443-9511, chensc@mail.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, DIDARP Review.

    Date: March 30, 2012.

    Time: 12 p.m. to 4 p.m.

    Agenda: To review and evaluate grant applications.

    Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard Rockville, MD 20852 (Telephone Conference Call).

    Contact Person: Nadine Rogers, Ph.D., Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4229, MSC 9550, Bethesda, MD 20892-9550, 301-402-2105, rogersn2@nida.nih.gov.

    (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

    Start Signature

    Dated: February 24, 2012.

    Jennifer S. Spaeth,

    Director, Office of Federal Advisory Committee Policy.

    End Signature End Preamble

    [FR Doc. 2012-5039 Filed 3-1-12; 8:45 am]

    BILLING CODE 4140-01-P